Houston's Karim and Mansour Arem won second place for their ZWITA Spicy Traditional Harissa last year. Photo courtesy of H-E-B

For nine years, H-E-B has been a star maker. Through its annual Quest for Texas Best competition, small companies have become literal household names, filling pantries across the state. Now, a new crop of products has the chance to be crowned as the high-stakes contest seeks entries for its 10th anniversary year.

H-E-B has announced that the Quest for Texas Best is taking applications from February 22 through April 6. Small business owners and entrepreneurs across the state can submit their unique and innovative products to win a combined $70,000 in cash prizes and the opportunity to feature their products on H-E-B shelves.

Since the competition started nine years ago, H-E-B has discovered over 960 exceptional products across the Lone Star State. These have included various food and non-food items, including cookies, coffees, beauty items, toys, home goods, and even roasted crickets. The contest has awarded nearly $2 million in prize money and provided valuable marketing, mentoring, and supplemental support to its winners.

Houston has always been well-represented among the winners. Last year, Karim and Mansour Arem won second place and a $15,000 prize for their ZWITA Spicy Traditional Harissa

To be considered for the contest, interested suppliers and manufacturers can submit details about their products online between February 22 and April 6. After the Call for Entries period is complete, H-E-B's Business Development Managers will select the top applicants who will present their products before a panel of judges chosen by H-E-B on August 9 at Fair Park in Dallas.

The panel of judges will determine the top four winning products and award $25,000 to the Grand Prize winner, the title of "Texas Best," and placement on H-E-B store shelves. The first-place winner will receive $20,000, the second-place winner will receive $15,000, and the third-place winner will receive $10,000.

"As we continue to expand the opportunities for small businesses in Texas and diversify our supplier base through programs like Quest for Texas Best, we look forward to seeing what our fellow Texans bring to the judges' table during the 2023 competition," said James Harris, Sr. Director of Diversity & Inclusion and Supplier Diversity for H-E-B, via a release.

------

This article originally ran on CultureMap.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Axiom Space-tested cancer drug advances to clinical trials

mission critical

A cancer-fighting drug tested aboard several Axiom Space missions is moving forward to clinical trials.

Rebecsinib, which targets a cancer cloning and immune evasion gene, ADAR1, has received FDA approval to enter clinical trials under active Investigational New Drug (IND) status, according to a news release. The drug was tested aboard Axiom Mission 2 (Ax-2) and Axiom Mission 3 (Ax-3). It was developed by Aspera Biomedicine, led by Dr. Catriona Jamieson, director of the UC San Diego Sanford Stem Cell Institute (SSCI).

The San Diego-based Aspera team and Houston-based Axiom partnered to allow Rebecsinib to be tested in microgravity. Tumors have been shown to grow more rapidly in microgravity and even mimic how aggressive cancers can develop in patients.

“In terms of tumor growth, we see a doubling in growth of these little mini-tumors in just 10 days,” Jamieson explained in the release.

Rebecsinib took part in the patient-derived tumor organoid testing aboard the International Space Station. Similar testing is planned to continue on Axiom Station, the company's commercial space station that's currently under development.

Additionally, the drug will be tested aboard Ax-4 under its active IND status, which was targeted to launch June 25.

“We anticipate that this monumental mission will inform the expanded development of the first ADAR1 inhibitory cancer stem cell targeting drug for a broad array of cancers," Jamieson added.

According to Axiom, the milestone represents the potential for commercial space collaborations.

“We’re proud to work with Aspera Biomedicines and the UC San Diego Sanford Stem Cell Institute, as together we have achieved a historic milestone, and we’re even more excited for what’s to come,” Tejpaul Bhatia, the new CEO of Axiom Space, said in the release. “This is how we crack the code of the space economy – uniting public and private partners to turn microgravity into a launchpad for breakthroughs.”

Chevron enters the lithium market with major Texas land acquisition

to market

Chevron U.S.A., a subsidiary of Houston-based energy company Chevron, has taken its first big step toward establishing a commercial-scale lithium business.

Chevron acquired leaseholds totaling about 125,000 acres in Northeast Texas and southwest Arkansas from TerraVolta Resources and East Texas Natural Resources. The acreage contains a high amount of lithium, which Chevron plans to extract from brines produced from the subsurface.

Lithium-ion batteries are used in an array of technologies, such as smartwatches, e-bikes, pacemakers, and batteries for electric vehicles, according to Chevron. The International Energy Agency estimates lithium demand could grow more than 400 percent by 2040.

“This acquisition represents a strategic investment to support energy manufacturing and expand U.S.-based critical mineral supplies,” Jeff Gustavson, president of Chevron New Energies, said in a news release. “Establishing domestic and resilient lithium supply chains is essential not only to maintaining U.S. energy leadership but also to meeting the growing demand from customers.”

Rania Yacoub, corporate business development manager at Chevron New Energies, said that amid heightening demand, lithium is “one of the world’s most sought-after natural resources.”

“Chevron is looking to help meet that demand and drive U.S. energy competitiveness by sourcing lithium domestically,” Yacoub said.

---

This article originally appeared on EnergyCapital.